Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells 24,474 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider John J. Boniface sold 24,474 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $9.04, for a total value of $221,244.96. Following the completion of the transaction, the insider now owns 139,771 shares in the company, valued at approximately $1,263,529.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sera Prognostics Price Performance

SERA opened at $9.10 on Friday. Sera Prognostics, Inc. has a 52 week low of $1.52 and a 52 week high of $10.44. The business’s fifty day simple moving average is $8.47 and its 200 day simple moving average is $5.03.

Hedge Funds Weigh In On Sera Prognostics

A number of institutional investors have recently bought and sold shares of SERA. Sanders Morris Harris LLC increased its stake in shares of Sera Prognostics by 22.6% during the third quarter. Sanders Morris Harris LLC now owns 445,105 shares of the company’s stock valued at $828,000 after purchasing an additional 81,933 shares in the last quarter. Resource Consulting Group Inc. bought a new position in shares of Sera Prognostics during the fourth quarter valued at approximately $265,000. Squarepoint Ops LLC bought a new position in shares of Sera Prognostics during the first quarter valued at approximately $65,000. Bank of New York Mellon Corp bought a new position in shares of Sera Prognostics during the first quarter valued at approximately $50,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Sera Prognostics during the first quarter valued at approximately $46,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.